Business
Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference
REDWOOD CITY, Calif., May 14, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference being held from June 2-4, 2026 in New York.
About this update from Adicet Bio, Inc.
REDWOOD CITY, Calif., May 14, 2026 --( BUSINESS WIRE )--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference being held from June 2-4, 2026 in New York. Details of the event are as follows: Date: Thursday, June 4, 2026 Time: 7:35a.m. ET The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com . An archived replay will be available for 30 days following the presentation. About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com . View source version on businesswire.com: https://www.businesswire.com/news/home/20260514519453/en/ Contacts Adicet Bio., Inc. Investor and Media Contacts Anne Bowdidge [email protected] Penelope Belnap Precision AQ [email protected]